



(11) **EP 2 698 386 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 19/00 ^(2006.01) **A61K 38/00** ^(2006.01)
A61P 37/06 ^(2006.01) **C07K 14/47** ^(2006.01)
C07K 16/18 ^(2006.01) **C12P 21/02** ^(2006.01)
C12N 15/09 ^(2006.01) **C07K 14/705** ^(2006.01)

(48) Corrigendum issued on:
07.02.2018 Bulletin 2018/06

(86) International application number:
PCT/JP2012/058912

(45) Date of publication and mention
of the grant of the patent:
20.12.2017 Bulletin 2017/51

(87) International publication number:
WO 2012/141026 (18.10.2012 Gazette 2012/42)

(21) Application number: **12770896.4**

(22) Date of filing: **02.04.2012**

(54) **FUSION PROTEIN**
FUSIONSPROTEIN
PROTÉINE DE FUSION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(56) References cited:
WO-A1-2011/013470 WO-A2-03/068822
WO-A2-2004/110472 DE-A1- 10 160 248
JP-A- 9 077 800 JP-A- 2007 505 643
JP-A- 2011 032 188

(30) Priority: **13.04.2011 JP 2011088762**

(43) Date of publication of application:
19.02.2014 Bulletin 2014/08

(73) Proprietor: **Nihon Pharmaceutical Co., Ltd.**
Chuo-ku,
Tokyo 104-0044 (JP)

(72) Inventors:
• **KOGURE, Takahisa**
Chiba 286-0825 (JP)
• **NAKAJIMA, Kenji**
Osaka 598-0061 (JP)
• **HOMMA, Masayuki**
Narita-shi
Chiba 286-0825 (JP)

(74) Representative: **Patentanwälte**
Ruff, Wilhelm, Beier, Dauster & Partner mbB
Kronenstraße 30
70174 Stuttgart (DE)

- **CHANG T ET AL: "Selective recognition and elimination of nicotinic acetylcholine receptor-reactive B cells by a recombinant fusion protein AChR-Fc in myasthenia gravis in vitro", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 227, no. 1-2, 8 October 2010 (2010-10-08), pages 35-43, XP027288214, ISSN: 0165-5728 [retrieved on 2010-08-19]**
- **ZOCHER M ET AL: "SPECIFIC DEPLETION OF AUTOREACTIVE B LYMPHOCYTES BY A RECOMBINANT FUSION PROTEIN IN VITRO AND IN VIVO", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 15, no. 7, 1 July 2003 (2003-07-01), pages 789-796, XP001155918, ISSN: 0953-8178, DOI: 10.1093/INTIMM/DXG076**
- **ZOCHER M. ET AL.: 'Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo' INT. IMMUNOL. vol. 15, no. 7, 2003, pages 789 - 796, XP001155918**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 698 386 B8

- **TSOULOUFIS T. ET AL.: 'Reconstitution of conformationally dependent epitopes on the N-terminal extracellular domain of the human muscle acetylcholine receptor alpha subunit expressed in Escherichia coli: implications for myasthenia gravis therapeutic approaches' INT. IMMUNOL. vol. 12, no. 9, 2000, pages 1255 - 1265, XP008148987**